-+ 0.00%
-+ 0.00%
-+ 0.00%

Proximus (ENXTBR:PROX) Q3 Results Expose A Deeper Profitability Problem

Simply Wall St·11/01/2026 01:23:27
Listen to the news

Proximus walked into its Q3 2026 results with the stock pinned near €6.21 and a trailing P/E of 5.4x, priced more like a problem than a steady telecom utility. The headline from the release is not spectacular revenue; it is pressure on profitability, with trailing net margin at 6.2% compared with 7.4% a year earlier.

The share price has barely moved over the past month, yet the earnings print underlines a margin squeeze that appears more serious than the calm ticker suggests. Short term optimism in the valuation now collides with a tougher profit story.

Attracted by the low P/E on Proximus but concerned that shrinking profitability could indicate a value trap instead of a bargain. Compare it with telecoms and other defensive stocks from our 217 resilient stocks with low risk scores

Q3 2026 Earnings Summary

  • Revenue, Q3 2026 vs. Q3 2025: €1,536 million vs. €1,540 million (flat, slight decline of 0.3%)
  • Net Income, Q3 2026 vs. Q3 2025: €96 million vs. €85 million (increase of 12.9%)
  • Basic EPS, Q3 2026 vs. Q3 2025: €0.2975 vs. €0.2633 (improvement of 13.0%)
  • Trailing 12-Month Net Income, Q3 2026 vs. Q3 2025: €374 million vs. €473 million (decline of 20.9%)

Proximus raised organic free cash flow guidance after an earlier Global rebound. Ask Charlie what made Proximus lift its cash flow guidance.

ENXTBR:PROX Trailing 12-Month Revenue & Expenses Breakdown as at Nov 2026
ENXTBR:PROX Trailing 12-Month Revenue & Expenses Breakdown as at Nov 2026

Evaluating Proximus: Cash Discipline Versus Execution Claims

Supporters argue Proximus can turn heavy investment and efficiency plans into stronger long term cash generation rather than just bigger infrastructure.

"The main thing that has to go right is that Proximus executes on fiber-led CapEx discipline and automation driven savings, while stabilising Global EBITDA despite pressure on legacy SMS and voice."

The latest quarter offers partial support. Global EBITDA reached €35m and full year guidance increased to a range of €125 to €135m, which points to earlier progress in that unit. Cash CapEx is now expected slightly below €1.3b and organic free cash flow guidance moved up to about €100m, suggesting the capital intensity and cash discipline side of the story is starting to show up in reported numbers.

The price and this Narrative do not agree. → Uncover what this Narrative says Proximus is actually worth.

Proximus Global Turnaround: Early Progress, Key Risks Intact

Bearish investors worry that Proximus will not shift Global fast enough away from legacy traffic into higher margin digital services, keeping earnings under strain.

"Although the reset of Proximus Global ambitions and ongoing cost synergies are expected to stabilize profitability, the structural shift away from legacy P2P voice, messaging and SMS CPaaS toward omnichannel and digital identity may take longer than anticipated. This may keep Global EBITDA at the lower end of the guided range and weigh on group earnings."

Q3 Global EBITDA of €35m and a raised full year range of €125 to €135m show progress against that fear. However, margin pressure remains visible in higher Global OpEx and a weaker group trailing net margin of 6.2% versus 7.4% a year earlier. The reset is working earlier than bears assumed, but not enough to dismiss the concern that the shift in revenue mix may take longer and keep profitability fragile.

Hunt For Mispriced Cash Generators

Proximus shows how a steady ticker can mask complex earnings dynamics beneath the surface. The real opportunity sits in finding companies that could be misjudged before broader market expectations adjust.

  • Company 1 - 42% below our estimate - sell modular servers and data center platforms to large AI customers building full-stack infrastructure.
  • Company 2 - 48% below our estimate - turn a record backlog of complex, tech-heavy building projects into installation, monitoring and maintenance contracts.
  • Company 3 - 41% below our estimate - supply oncology software that hospitals adopt when replacing legacy planning tools with AI guided treatment.

Three companies from the same screener. Open all 196 potentially undervalued companies →